Immunovant Inc. Common Stock vs Relay Therapeutics Inc. Common Stock — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Relay Therapeutics Inc. Common Stock trades at $17.39 (market cap $3.94B). The key difference: Immunovant Inc. Common Stock is the larger of the two by market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| IMVT | RLAY | |
|---|---|---|
Market Cap | $6.62B | $3.94B |
Volume | 1,131,364 | 3,432,928 |
Sector | Health | Health |
52-Week High | $44.96 | $20.75 |
52-Week Low | $17.03 | $6.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $5.72B | $3.06B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →